Login
$IBRX
$5.96 -$0.02 (0.33%) After hours

$IBRX SEC Filings

Filed On Filing
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million

09 Nov 2026 8-K: Regulation FD Disclosure

CULVER CITY, Calif., November 9, 2026—ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005, a randomized, ...

14 Oct 2026 8-K: Regulation FD Disclosure

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

06 Oct 2026 Form 4: Simon Barry J., Director

Sold 25,000 shares ($269K)

06 Oct 2026 Form 4: Cohen Cheryl, Director

Received 55,979 shares by exercise or conversion ($167K) · Sold 81,056 shares ($851K)

05 Oct 2026 144
02 Oct 2026 144
06 Aug 2026 SCHEDULE 13D/A
04 Aug 2026 10-Q
04 Aug 2026 8-K: Results of Operations and Financial Condition

CULVER CITY, Calif. August 4, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30, 2026. Net product revenue reached $5...

30 Jul 2026 8-K: Regulation FD Disclosure

CULVER CITY, Calif., July 29, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has grant...

06 Jul 2026 Form 4: Cohen Cheryl, Director

Received 55,979 shares by exercise or conversion ($167K) · Sold 131,210 shares ($1.25M)

06 Jul 2026 Form 4: Selecky Christobel, Director

Received 159,478 shares by exercise or conversion ($476K) · Sold 159,478 shares ($1.44M)

02 Jul 2026 144
01 Jul 2026 Form 4: Selecky Christobel, Director

Received 95,722 shares by exercise or conversion ($281K) · Sold 95,722 shares ($862K) · Received 1,000 shares by exercise or conversion ($2.98K) · 1 more

01 Jul 2026 144
30 Jun 2026 144
29 Jun 2026 144
26 Jun 2026 Form 4: Simon Barry J., Director

Sold 25,000 shares ($197K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support